Logo image of RNAZ

TRANSCODE THERAPEUTICS INC (RNAZ) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RNAZ - US89357L5012 - Common Stock

8.74 USD
-0.2 (-2.24%)
Last: 1/20/2026, 5:20:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RNAZ. RNAZ was compared to 525 industry peers in the Biotechnology industry. While RNAZ seems to be doing ok healthwise, there are quite some concerns on its profitability. RNAZ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year RNAZ has reported negative net income.
  • In the past year RNAZ has reported a negative cash flow from operations.
  • RNAZ had negative earnings in each of the past 5 years.
  • RNAZ had a negative operating cash flow in each of the past 5 years.
RNAZ Yearly Net Income VS EBIT VS OCF VS FCFRNAZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • RNAZ's Return On Assets of -519.73% is on the low side compared to the rest of the industry. RNAZ is outperformed by 94.48% of its industry peers.
  • RNAZ has a worse Return On Equity (-1904.95%) than 81.14% of its industry peers.
Industry RankSector Rank
ROA -519.73%
ROE -1904.95%
ROIC N/A
ROA(3y)-273.44%
ROA(5y)-214.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAZ Yearly ROA, ROE, ROICRNAZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

  • RNAZ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAZ Yearly Profit, Operating, Gross MarginsRNAZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for RNAZ has been increased compared to 1 year ago.
  • Compared to 5 years ago, RNAZ has more shares outstanding
  • RNAZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNAZ Yearly Shares OutstandingRNAZ Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
RNAZ Yearly Total Debt VS Total AssetsRNAZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • RNAZ has an Altman-Z score of -31.67. This is a bad value and indicates that RNAZ is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of RNAZ (-31.67) is worse than 87.81% of its industry peers.
  • RNAZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -31.67
ROIC/WACCN/A
WACCN/A
RNAZ Yearly LT Debt VS Equity VS FCFRNAZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • RNAZ has a Current Ratio of 1.60. This is a normal value and indicates that RNAZ is financially healthy and should not expect problems in meeting its short term obligations.
  • RNAZ has a Current ratio of 1.60. This is in the lower half of the industry: RNAZ underperforms 79.62% of its industry peers.
  • A Quick Ratio of 1.60 indicates that RNAZ should not have too much problems paying its short term obligations.
  • The Quick ratio of RNAZ (1.60) is worse than 78.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.6
RNAZ Yearly Current Assets VS Current LiabilitesRNAZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

  • RNAZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.47%, which is quite impressive.
EPS 1Y (TTM)95.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
  • RNAZ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 147.39% yearly.
EPS Next Y99.7%
EPS Next 2Y41.41%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.39%

3.3 Evolution

RNAZ Yearly Revenue VS EstimatesRNAZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2028 2029 2030 10M 20M 30M 40M 50M
RNAZ Yearly EPS VS EstimatesRNAZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -200K -400K -600K -800K -1M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RNAZ. In the last year negative earnings were reported.
  • Also next year RNAZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAZ Price Earnings VS Forward Price EarningsRNAZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAZ Per share dataRNAZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K

4.3 Compensation for Growth

  • RNAZ's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.41%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for RNAZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TRANSCODE THERAPEUTICS INC

NASDAQ:RNAZ (1/20/2026, 5:20:02 PM)

8.74

-0.2 (-2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15
Earnings (Next)N/A
Inst Owners2.83%
Inst Owner Change0%
Ins Owners0.14%
Ins Owner Change0%
Market Cap8.04M
Revenue(TTM)N/A
Net Income(TTM)-27.16M
Analysts82.86
Price TargetN/A
Short Float %7.17%
Short Ratio0.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.64
P/tB 5.64
EV/EBITDA N/A
EPS(TTM)-1462.72
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-15.78
FCFYN/A
OCF(TTM)-15.78
OCFYN/A
SpS0
BVpS1.55
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -519.73%
ROE -1904.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-273.44%
ROA(5y)-214.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.6
Quick Ratio 1.6
Altman-Z -31.67
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)51.71%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.01%
EPS Next Y99.7%
EPS Next 2Y41.41%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.39%
EBIT growth 1Y-16.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.63%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSCODE THERAPEUTICS INC / RNAZ FAQ

What is the ChartMill fundamental rating of TRANSCODE THERAPEUTICS INC (RNAZ) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RNAZ.


What is the valuation status for RNAZ stock?

ChartMill assigns a valuation rating of 1 / 10 to TRANSCODE THERAPEUTICS INC (RNAZ). This can be considered as Overvalued.


What is the profitability of RNAZ stock?

TRANSCODE THERAPEUTICS INC (RNAZ) has a profitability rating of 0 / 10.


Can you provide the financial health for RNAZ stock?

The financial health rating of TRANSCODE THERAPEUTICS INC (RNAZ) is 5 / 10.


What is the expected EPS growth for TRANSCODE THERAPEUTICS INC (RNAZ) stock?

The Earnings per Share (EPS) of TRANSCODE THERAPEUTICS INC (RNAZ) is expected to grow by 99.7% in the next year.